主动监测方案中前列腺癌患者穿刺活检组织携带PTEN和MYC改变
研究对54例纳入两项主动监测方案、穿刺Gleason评分3+3的前列腺癌患者活检组织行全外显子组测序,其中27例因随访2年内升级(Gleason评分>3+3)退出主动监测,另27例主动监测≥4年无重新分级证据。34%活检可见体细胞拷贝数异常,PTEN缺失和MYC扩增仅或优先见于非惰性患者。
要点
- 34%的Gleason评分3+3活检可见体细胞拷贝数异常。
- PTEN缺失和MYC扩增仅或优先见于非惰性患者。
- 上述分子发现经同一组织块免疫组化证实。
核心结论
- 在主动监测患者Gleason评分3+3穿刺活检中可检测到富集于侵袭性肿瘤的基因组特征。
研究设计与样本
- 对纳入两项主动监测方案的54例前列腺癌患者Gleason评分3+3活检组织行全外显子组测序。
- 非惰性人群27例,为随访2年内因升级(随访活检发现Gleason评分>3+3)退出主动监测者。
- 潜在惰性人群27例,为主动监测≥4年无重新分级证据者。
主要发现
- 研究队列Gleason评分3+3活检中34%显示全基因组体细胞拷贝数异常明确证据。
- 上述拷贝数异常中39%来自潜在惰性人群,61%来自非惰性人群。
- 单核苷酸变异等位基因分数低,包括SPOP基因常见F133C突变。
- 研究队列基因组改变较少,可见8p、13q、16q、21q单等位缺失及8q罕见扩增,两类主动监测人群均存在。
- PTEN缺失和MYC扩增仅见于少数病例,分别仅或优先见于非惰性患者,并经同一组织块免疫组化证实。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量小。
- 分析为回顾性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic characterization of prostate cancer (PCa) biopsies may improve criteria for the selection of patients suitable for active surveillance (AS). OBJECTIVE: To identify somatic genomic aberrations associated with adverse outcome as AS protocol exclusion indicators. DESIGN, SETTING AND PARTICIPANTS: Whole-exome sequencing profiles were generated for Gleason score (GS)=3+3 biopsies obtained from 54 PCa patients enrolled in two AS protocols. Patients were selected as representative of a nonindolent population, consisting of 27 patients who dropped out from AS due to upgrading (ie, finding of GS>3+3 at a follow-up biopsy) within 2 yr, and a potentially indolent population, consisting of 27 patients in AS for ≥4 yr without any evidence of reclassification. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The genomic alteration landscape of core biopsies was analyzed using an integrated computational pipeline and correlated with patient reclassification due to upgrading. RESULTS AND LIMITATIONS: Of all the GS=3+3 biopsies of the study cohort, 34% showed clear evidence of somatic copy number aberrations along the genome. Of these, 39% came from the potentially indolent and 61% from the nonindolent population. Single-nucleotide variants demonstrated low allelic fractions and included a common F133C mutation in the SPOP gene. The minimally altered genomic landscape of the study cohort presented a distinct set of monoallelic deletions, including on 8p, 13q, 16q, and 21q, and rare amplifications of 8q, which were observed in both AS patient populations. Concerning lesions typically associated with adverse outcome, PTEN deletions and MYC amplification, though observed in a small number of cases, were detected exclusively or preferentially, respectively, in nonindolent patients. Such molecular findings were confirmed by immunohistochemistry on the same tissue blocks. The small sample size and the retrospective nature of the analysis represent the main study limitations. CONCLUSIONS: Genomic features enriched in aggressive tumors can be detected in GS=3+3 core biopsies of AS patients. PATIENT SUMMARY: PTEN and MYC alterations at the time of diagnosis would deserve investigation in larger cohorts of AS patients to assess their potential as biomarkers for a more precise/earlier identification of patients at risk of reclassification.
引用
- Gandellini P, Casiraghi N, Rancati T, et al. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. Eur Urol Oncol. 2018. PMID: 31200842. doi:10.1016/j.euo.2018.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。